Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 1, 1996, Pages 41-47

  Linnet, Kristian ^a   Wiborg, Ove ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; NEUROLEPTIC AGENT; PERPHENAZINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE;

EID: 0029738332     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90165-4     Document Type: Article

References (26)

1. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993;3:61-70.
2. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
3. Dahl-Puustinen ML, Lidén A, Aim C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989;46:78-81.
4. Jørgensen A. Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chasseau LF, editors. Progress in drug metabolism; vol 9. London: Taylor & Francis, 1986:111-74.
5. Murray M. P450 enzymes: inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992;23:132-46.
6. Larsen NE, Hansen LB, Knudsen P. Quantitative determination of perphenazine and its dealkylated metabolite using high-performance liquid chromatography. J Chromatogr 1985;341:818-24.
7. Hansen LB, Larsen NE, Gulmann N. Dose response relationships of perphenazine in treatment of acute psychoses. Psychopharmacology 1982;78:112-5.
8. Heim MH, Meyer VA. Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990;336:529-32.
9. Spurr NK, Gough AC, Smith CAD, Wolf CR. Genetic analysis of cytochrome P450 system. Methods Enzymol 1991;206:149-66.
10. Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, et al. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991;1:26-32.
11. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, et al. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993;3:256-63.
12. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci 1993;90:11825-9.
13. Agúndez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995;57:265-9.
14. Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brøgger A, et al. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994;4:47-57.
15. Spina E, Martines C, Caputi AP, Cobaleda J, Pinas B, Carrillo JA, et al. Debrisoquine oxidation phenotype during neuroleptic monotherapy. Eur J Clin Pharmacol 1991;41:467-70.
16. Hansen LB, Larsen NE. Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology 1977;53:127-30.
17. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin reuptake inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
18. von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991;49:234-40.
19. LLerena A, Alm C, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992;14: 92-7.
20. Dahl ML, Ekqvist B, Widén J, Bertilsson L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991;84:99-102.
21. Meyer JW, Woggon B, Baumann P, Meyer UA. Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 1990;39:613-4.
22. Gram LF, Debruyne D, Caillard V, Boulenger JP, Lacotte J, Moulin M, et al. Substantial rise in sparteine metabolic ratio during haloperidol treatment. Br J Clin Pharmacol 1989;27:272-5.
23. Arthur H, Dahl ML, Siwers B, Sjöqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995;15: 211-6.
24. Dahl SG. Plasma level monitoring of antipsychotic drugs: clinical utility. Clin Pharmacokinet 1986;11:36-61.
25. Licht RW, Thomsen K, Olesen OV, Poulsen JH. Interindividual variation in serum zuclopenthixol and perphenazine concentrations in orally treated patients. Nord J Psychiatry 1994;48:173-5.
26. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, et al. In vitro methods for assessing human hepatic drug metabolism: their use in drug development. Drug Metab Rev 1993;25:453-84.